Genetically modified vaccines augment the efficacy of cancer surgery and chemotherapy

Folia Biologica

Volumn 55, Issue 6, 2009, Pages 199-200

  Bubeník, Jan ^a,b  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; WART VIRUS VACCINE;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CYTOKINE PRODUCTION; DNA MODIFICATION; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; GENE THERAPY; GENETIC ENGINEERING; GENOME; HUMAN; HUMAN PAPILLOMA VIRUS 16 ASSOCIATED TUMOR; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 16 ASSOCIATED TUMOR; IMMUNOSTIMULATION; METASTASIS; MINIMAL RESIDUAL DISEASE; NEOPLASM; NONHUMAN; ONCOGENE RAS; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; VIRAL GENE THERAPY;

EID: 76049105837     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Bubeník, J., Šímová, J., Bubení ková, D., Zeuthen, J., Indrová, M. (1995a) Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J. Cancer Res. Clin. Oncol. 121, 39-43.
2. Bubeník, J., Bubeníková, D., Ší mová, J., Lotzová, E. (1995b) Interleukin 2 (IL-2) and gene therapy of cancer: treatment of myeloid leukaemia with irradiated genetically modified IL-2-producing cell vaccine. J. Exp. Clin. Cancer Res. 14 (Suppl), 83-86.
3. Bubeník, J. (1996a) Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol. Ther. 69, 1-14.
4. Bubeník, J. (1996b) Gene transfer for immunotherapy of cancer. Gene Ther. 3, 944-945.
5. Bubeník, J., Šímová, J., Há jková, R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková, E., Vonka, V. (1999) Interleukin-2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int. J. Oncol. 14, 593-597.
6. Bubeník, J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Indrová, M. (2003) Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21, 891-896.
7. Bubeník, J., Šímová, J. (2005) Minimal residual disease as the target for immunotherapy and gene therapy of cancer. Oncol. Rep. 14, 1377-1380.
8. Bubeník, J. (2006a) Human papillomavirus (HPV) and HPV - associated tumour vaccines. Folia Biol. (Praha) 52, 45-46.
9. Bubeník, J. (2006b) Depletion of Treg cells augments the therapeutic effect of cancer vaccines. Folia Biol. (Praha) 52, 202-204.
10. Bubeník, J. (2008) Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV16)-associated tumours. Curr. Cancer Drug Targets 8, 180-186.
11. Bubeník, J., Šímová, J. (2009) Genetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumours: adjuvant treatment of minimal residual disease after surgery/chemotherapy. JBUON 14, S169-174.
12. Cross, D., Burmester, J. K. (2004) The promise of molecular profiling for cancer identification and treatment. Clin. Med. Res. 2, 147-150.
13. Indrová, M., Bubeník, J., Šímová, J., Bieblová, J., Jandlová, T., Šmahel, M., Vonka, V., Glazman-Kusnierczyk, H., Pajtasz-Piasecka, E., Radzikowski, C., Mikyšková, R. (2001) Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol. Rep. 8, 1371-1374.
14. Indrová, M., Bubeník, J., Mikyšková, R., Vonka, V., Šmahel, M., Žák, R., Šímová , J, Bieblová, J., Mendoza, L., Jandlová, T. (2002) Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. Int. J. Oncol. 20, 643-646.
15. Indrová, M., Bubeník, J., Mikyšková, R., Mendoza, L., Šímová, J., Bieblová, J., Jandlová, T., Jinoch, P., Šmahel, M., Vonka, V., Pajtasz-Piasecka, E. (2003) Chemoimmunotherapy in mice carrying HPV16-associated, MHC class 1+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int. J. Oncol. 22, 691-695.
16. Indrová, M., Bieblová, J., Jandlová, T., Vonka, V., Pajtasz-Piasecka, E., Reiniš, M. (2006) Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV16-associated MHC class I-proficient and -deficient tumours. Int. J. Oncol. 28, 253-259.
17. Mikyšková, R., Bubeník, J., Mendoza, L., Vonka, V., Šmahel, M., Šímová, J., Jandlová, T. (2001) Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin. Exp. Metastasis 18, 581-587.
18. Mikyšková, R., Indrová, M., Ší mová, J., Jandlová, T., Bieblová, J, Jinoch, P., Bubeník, J., Vonka, V. (2004) Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int. J. Oncol. 24, 161-167.
19. Mikyšková, R., Bubeník, J., Vonka, V., Šmahel, M., Indrová, M., Bieblová, J., Šimová , J., Jandlová, T. (2005) Immune escape phenothype of HPV16-associated tumours: MHC class I expression changes during progression and therapy. Int. J. Oncol. 26, 521-528.
20. Russell, H. V., Strother, D., Mei, Z., Rill, D., Popek, E., Biagi, E., Yvon, E., Brenner, M., Rousseau, R. (2008) A Phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J. Immunother. 31, 812-819.
21. Sobotková, E., Dušková, M., Tachezy, R., Petračková, M., Vonka, V. (2009) Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells. Oncol. Rep. 21, 793-799.
22. Šmahel, M., Sobotková, E., Bubeník, J., Šimová, J., Žák, R., Ludvíková, V., Hájková, R., Kovařík, J., Jelínek, F., Povýšil, C., Marinov, J., Vonka, V. (2001) Metastatic MHC class I negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84, 374-380.
23. Vlk, V., Rössner, P., Indrová, M., Bubeník, J., Sobota, V. (1998) Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int. J. Cancer 76, 115-119.